LT3310379T - Dnr vakcina, nukreipta į vegfr-2, skirta kompleksiniam gydymui - Google Patents
Dnr vakcina, nukreipta į vegfr-2, skirta kompleksiniam gydymuiInfo
- Publication number
- LT3310379T LT3310379T LTEP16736381.1T LT16736381T LT3310379T LT 3310379 T LT3310379 T LT 3310379T LT 16736381 T LT16736381 T LT 16736381T LT 3310379 T LT3310379 T LT 3310379T
- Authority
- LT
- Lithuania
- Prior art keywords
- vegfr
- dna vaccine
- integrated treatment
- vaccine targeted
- targeted
- Prior art date
Links
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 title 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001803 | 2015-06-18 | ||
| PCT/EP2016/001004 WO2016202459A1 (en) | 2015-06-18 | 2016-06-16 | Vegfr-2 targeting dna vaccine for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3310379T true LT3310379T (lt) | 2019-12-27 |
Family
ID=53476620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16736381.1T LT3310379T (lt) | 2015-06-18 | 2016-06-16 | Dnr vakcina, nukreipta į vegfr-2, skirta kompleksiniam gydymui |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10905752B2 (enExample) |
| EP (2) | EP3310379B1 (enExample) |
| JP (1) | JP6947649B2 (enExample) |
| KR (2) | KR20250024816A (enExample) |
| CN (1) | CN107995868B (enExample) |
| AU (1) | AU2016278588B2 (enExample) |
| BR (1) | BR112017027378A2 (enExample) |
| CA (1) | CA2989247C (enExample) |
| DK (1) | DK3310379T3 (enExample) |
| ES (2) | ES2760699T3 (enExample) |
| HU (1) | HUE046631T2 (enExample) |
| IL (1) | IL256076A (enExample) |
| LT (1) | LT3310379T (enExample) |
| MX (1) | MX2017016183A (enExample) |
| PL (2) | PL3310379T3 (enExample) |
| RU (1) | RU2018101722A (enExample) |
| SI (1) | SI3310379T1 (enExample) |
| WO (1) | WO2016202459A1 (enExample) |
| ZA (1) | ZA201708439B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3534935A1 (en) * | 2016-11-04 | 2019-09-11 | Vaximm AG | Wt1 targeting dna vaccine for combination therapy |
| KR20190117603A (ko) | 2017-02-17 | 2019-10-16 | 백심 아게 | 신규 vegfr-2 표적화 면역요법상 접근법 |
| SG11201908528UA (en) * | 2017-03-17 | 2019-10-30 | Vaximm Ag | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
| US20210213121A1 (en) * | 2018-09-05 | 2021-07-15 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| AU2021208400A1 (en) * | 2020-01-13 | 2022-08-11 | Vaximm Ag | Salmonella-based DNA vaccines in combination with an antibiotic |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094410B2 (en) | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| BR112014015706A2 (pt) | 2011-12-22 | 2020-10-27 | Vaximm Ag | método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a |
| SG11201500054QA (en) * | 2012-07-05 | 2015-03-30 | Vaximm Ag | Dna vaccine for use in pancreatic cancer patients |
| MX375442B (es) * | 2012-09-21 | 2025-03-06 | Intensity Therapeutics Inc | Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. |
| SG11201506052PA (en) * | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| DK2988762T3 (en) * | 2013-04-25 | 2018-07-16 | Vaximm Ag | SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1 |
| PL3082850T3 (pl) * | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | Celowana szczepionka DNA MSLN w immunoterapii nowotworu |
| KR20190117603A (ko) * | 2017-02-17 | 2019-10-16 | 백심 아게 | 신규 vegfr-2 표적화 면역요법상 접근법 |
| SG11201908528UA (en) * | 2017-03-17 | 2019-10-30 | Vaximm Ag | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
-
2016
- 2016-06-16 KR KR1020257001040A patent/KR20250024816A/ko active Pending
- 2016-06-16 PL PL16736381T patent/PL3310379T3/pl unknown
- 2016-06-16 MX MX2017016183A patent/MX2017016183A/es unknown
- 2016-06-16 ES ES16736381T patent/ES2760699T3/es active Active
- 2016-06-16 LT LTEP16736381.1T patent/LT3310379T/lt unknown
- 2016-06-16 RU RU2018101722A patent/RU2018101722A/ru not_active Application Discontinuation
- 2016-06-16 SI SI201630549T patent/SI3310379T1/sl unknown
- 2016-06-16 DK DK16736381.1T patent/DK3310379T3/da active
- 2016-06-16 BR BR112017027378-0A patent/BR112017027378A2/pt not_active Application Discontinuation
- 2016-06-16 CN CN201680035593.2A patent/CN107995868B/zh active Active
- 2016-06-16 US US15/737,659 patent/US10905752B2/en active Active
- 2016-06-16 EP EP16736381.1A patent/EP3310379B1/en active Active
- 2016-06-16 PL PL19205420.3T patent/PL3626262T3/pl unknown
- 2016-06-16 ES ES19205420T patent/ES2994561T3/es active Active
- 2016-06-16 CA CA2989247A patent/CA2989247C/en active Active
- 2016-06-16 AU AU2016278588A patent/AU2016278588B2/en active Active
- 2016-06-16 WO PCT/EP2016/001004 patent/WO2016202459A1/en not_active Ceased
- 2016-06-16 KR KR1020187001398A patent/KR20180037948A/ko not_active Ceased
- 2016-06-16 EP EP19205420.3A patent/EP3626262B1/en active Active
- 2016-06-16 HU HUE16736381A patent/HUE046631T2/hu unknown
- 2016-06-16 JP JP2017565248A patent/JP6947649B2/ja active Active
-
2017
- 2017-12-04 IL IL256076A patent/IL256076A/en unknown
- 2017-12-12 ZA ZA2017/08439A patent/ZA201708439B/en unknown
-
2020
- 2020-11-30 US US17/107,203 patent/US20210077605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291932B2 (en) | Nanoparticle compositions for sustained therapy | |
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| IL296080B1 (en) | Method for treating cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| DK3393510T3 (da) | Zikavirusvaccine | |
| HRP20190194T1 (hr) | 17a,21-diesteri korteksolona, namijenjeni liječenju tumora | |
| EP3328873A4 (en) | TARGETED OLIGONUCLEOTIDES | |
| DK3234134T3 (da) | Målrettet rna-redigering | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| LT3119437T (lt) | Genų terapija, skirta pigmentiniam retinitui | |
| LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
| IL258684A (en) | Combination therapy for treating malignancies | |
| DK3262066T4 (da) | Genterapi | |
| HUE038541T2 (hu) | Rák kezelési módszerek | |
| DK3705102T3 (da) | Patientløftesystem | |
| DK3231444T3 (da) | Ny behandling | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| DK3393579T3 (da) | Øjenbehandlingssystem | |
| DE202014010318U8 (de) | Wärmebehandlungsvorrichtung | |
| PL3408417T3 (pl) | Sposób obróbki cieplnej | |
| LT3191514T (lt) | Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą | |
| IL262929A (en) | Composition, and application and pharmaceutical preparation thereof | |
| PT3134119T (pt) | Tratamento do cancro | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| SI3310379T1 (sl) | DNA cepivo, ki cilja VEGFR-2, za kombinacijsko terapijo |